NO20064771L - 2-pyridyl substituerte imidazoler som ALK5 og/eller ALK4 inhibitorer - Google Patents

2-pyridyl substituerte imidazoler som ALK5 og/eller ALK4 inhibitorer

Info

Publication number: NO20064771L
Authority: NO; Norway
Prior art keywords: alk5; pyridyl substituted; substituted imidazoles; alk4; inhibitors
Prior art date: 2004-04-21

Application number

NO20064771A

Other languages

English (en)

Norwegian (no)

Inventor

Dae-Kee Kim

Yung-Jue Bang

Hun-Taek Kim

Il-Sang Cho

Myoung-Soon Park

Young Jae An

Joon Hun Choi

Original Assignee

Ewha Univ Collaboration Founda

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-21

Filing date

2006-10-19

Publication date

2007-01-19

2006-10-19 Application filed by Ewha Univ Collaboration Founda filed Critical Ewha Univ Collaboration Founda

2007-01-19 Publication of NO20064771L publication Critical patent/NO20064771L/no

Links

125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 title abstract 2
102100034134 Activin receptor type-1B Human genes 0.000 title abstract 2
101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 title abstract 2
150000002460 imidazoles Chemical class 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title abstract 2
108020003175 receptors Proteins 0.000 abstract 3
102000005606 Activins Human genes 0.000 abstract 1
108010059616 Activins Proteins 0.000 abstract 1
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
102000009618 Transforming Growth Factors Human genes 0.000 abstract 1
108010009583 Transforming Growth Factors Proteins 0.000 abstract 1
239000000488 activin Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Ceramic Engineering (AREA)
Manufacturing & Machinery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Structural Engineering (AREA)
Inorganic Chemistry (AREA)
Materials Engineering (AREA)
Dermatology (AREA)
Gynecology & Obstetrics (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)

NO20064771A 2004-04-21 2006-10-19 2-pyridyl substituerte imidazoler som ALK5 og/eller ALK4 inhibitorer NO20064771L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR1020040027591A KR100749566B1 (ko)	2004-04-21	2004-04-21	Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
PCT/KR2004/002891 WO2005103028A1 (en)	2004-04-21	2004-11-09	2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors

Publications (1)

Publication Number	Publication Date
NO20064771L true NO20064771L (no)	2007-01-19

Family

ID=35196912

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20064771A NO20064771L (no)	2004-04-21	2006-10-19	2-pyridyl substituerte imidazoler som ALK5 og/eller ALK4 inhibitorer

Country Status (14)

Country	Link
US (1)	US7407958B2 (pt)
EP (1)	EP1620426A1 (pt)
JP (1)	JP4678540B2 (pt)
KR (1)	KR100749566B1 (pt)
CN (1)	CN1972921B (pt)
AU (1)	AU2004318777B2 (pt)
BR (1)	BRPI0418765B8 (pt)
CA (1)	CA2564442C (pt)
IL (1)	IL178757A (pt)
MX (1)	MXPA06012096A (pt)
NO (1)	NO20064771L (pt)
RU (1)	RU2348626C2 (pt)
WO (1)	WO2005103028A1 (pt)
ZA (1)	ZA200609626B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8410146B2 (en) *	2004-04-21	2013-04-02	Sk Chemicals Co., Ltd.	2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
US8420685B2 (en) *	2004-04-21	2013-04-16	Sk Chemicals Co., Ltd.	2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
US20080319012A1 (en) *	2004-04-21	2008-12-25	In2Gen Co., Ltd.	2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
TR201901929T4 (tr)	2005-02-08	2019-03-21	Genzyme Corp	TGFBeta'ya antikorlar.
US8865732B2 (en)	2008-03-21	2014-10-21	Novartis Ag	Heterocyclic compounds and uses thereof
WO2009115572A2 (en) *	2008-03-21	2009-09-24	Novartis Ag	Novel heterocyclic compounds and uses therof
WO2009146301A1 (en) *	2008-05-27	2009-12-03	Yale University	TARGETING TGF-β AS A THERAPY FOR ALZHEIMER'S DISEASE
US20100087486A1 (en) *	2008-05-30	2010-04-08	Hiroshi Nakamura	Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions
US8080568B1 (en) *	2010-06-29	2011-12-20	Ewha University - Industry Collaboration Foundation	2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
USRE47141E1 (en)	2010-06-29	2018-11-27	EWHA University—Industry Collaboration Foundation	Methods of treating fibrosis, cancer and vascular injuries
US8513222B2 (en)	2010-06-29	2013-08-20	EWHA University—Industry Collaboration Foundation	Methods of treating fibrosis, cancer and vascular injuries
WO2013078286A1 (en)	2011-11-22	2013-05-30	Cornell University	Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling
RU2475243C1 (ru) *	2012-02-16	2013-02-20	Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН)	Средство, обладающее антигипертензивной активностью
US9242969B2 (en)	2013-03-14	2016-01-26	Novartis Ag	Biaryl amide compounds as kinase inhibitors
UY36294A (es)	2014-09-12	2016-04-29	Novartis Ag	Compuestos y composiciones como inhibidores de quinasa
KR102434226B1 (ko) *	2016-06-30	2022-08-19	한미약품 주식회사	Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
AU2017329090B9 (en)	2016-09-19	2019-09-05	Novartis Ag	Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
CA3057969A1 (en)	2017-05-02	2018-11-08	Novartis Ag	Combination therapy
CN110066277B (zh) *	2018-01-24	2021-07-23	上海璎黎药业有限公司	芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
EP3969449B1 (en)	2019-05-13	2025-02-12	Novartis AG	New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
JP2023509760A (ja)	2020-01-08	2023-03-09	シンシスセラピューティクス，インコーポレイテッド	Ａｌｋ５阻害剤複合体およびその使用
CN112266378B (zh) *	2020-11-09	2021-10-12	延边大学	含吲唑结构的咪唑类衍生物及其制备方法和应用
US12240830B2 (en) *	2021-08-13	2025-03-04	Bisichem Co., Ltd.	Fused ring heteroaryl compounds and use thereof
CN115747214B (zh) *	2022-07-12	2025-11-18	安徽理工大学	Mlph基因在制备治疗尘肺病药物中的应用
CN121712526A (zh)	2023-06-13	2026-03-20	辛瑟斯治疗股份有限公司	抗cd5抗体及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5656644A (en) *	1994-07-20	1997-08-12	Smithkline Beecham Corporation	Pyridyl imidazoles
DK0786455T3 (da) *	1994-09-26	2004-03-29	Shionogi & Co	Imidazolderivater
US5965583A (en) *	1997-04-24	1999-10-12	Ortho-Mcneil Pharmaceutical, Inc.	Substituted imidazoles useful in the treatment of inflammatory disease
DE60001229T2 (de) *	1999-04-09	2003-10-30	Smithkline Beecham Corp., Philadelphia	Triarylimidazole
CO5271680A1 (es) *	2000-02-21	2003-04-30	Smithkline Beecham Corp	Compuestos
GB0007405D0 (en) *	2000-03-27	2000-05-17	Smithkline Beecham Corp	Compounds
EP1391452A4 (en)	2001-05-25	2005-10-26	Mochida Pharm Co Ltd	4-HYDROXPIPERIDIN DERIVATIVE ANALGETIC EFFECT
JP2003040888A (ja) *	2001-07-30	2003-02-13	Sankyo Co Ltd	イミダゾール誘導体
GB0218079D0 (en) *	2002-08-03	2002-09-11	Boatman Peter J	A pipe and pipe assembly
MXPA05002981A (es)	2002-09-18	2005-06-22	Pfizer Prod Inc	Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf).
US7250434B2 (en) *	2003-12-22	2007-07-31	Janssen Pharmaceutica N.V.	CCK-1 receptor modulators

2004
- 2004-04-21 KR KR1020040027591A patent/KR100749566B1/ko not_active Expired - Fee Related
- 2004-11-08 US US10/983,227 patent/US7407958B2/en not_active Expired - Lifetime
- 2004-11-09 AU AU2004318777A patent/AU2004318777B2/en not_active Ceased
- 2004-11-09 WO PCT/KR2004/002891 patent/WO2005103028A1/en not_active Ceased
- 2004-11-09 JP JP2007509388A patent/JP4678540B2/ja not_active Expired - Fee Related
- 2004-11-09 RU RU2006140989/04A patent/RU2348626C2/ru active
- 2004-11-09 CA CA2564442A patent/CA2564442C/en not_active Expired - Lifetime
- 2004-11-09 CN CN2004800433657A patent/CN1972921B/zh not_active Expired - Fee Related
- 2004-11-09 MX MXPA06012096A patent/MXPA06012096A/es active IP Right Grant
- 2004-11-09 BR BRPI0418765A patent/BRPI0418765B8/pt not_active IP Right Cessation
- 2004-11-09 EP EP04800071A patent/EP1620426A1/en not_active Withdrawn
2006
- 2006-10-19 NO NO20064771A patent/NO20064771L/no not_active Application Discontinuation
- 2006-10-19 IL IL178757A patent/IL178757A/en active IP Right Grant
- 2006-11-20 ZA ZA200609626A patent/ZA200609626B/xx unknown

Also Published As

Publication number	Publication date
AU2004318777B2 (en)	2008-10-16
JP4678540B2 (ja)	2011-04-27
IL178757A (en)	2011-08-31
EP1620426A1 (en)	2006-02-01
KR20050102752A (ko)	2005-10-27
JP2007533734A (ja)	2007-11-22
RU2006140989A (ru)	2008-05-27
ZA200609626B (en)	2008-08-27
AU2004318777A1 (en)	2005-11-03
CA2564442C (en)	2011-06-14
RU2348626C2 (ru)	2009-03-10
MXPA06012096A (es)	2007-11-20
US7407958B2 (en)	2008-08-05
US20050261299A1 (en)	2005-11-24
BRPI0418765B1 (pt)	2019-06-04
BRPI0418765A (pt)	2007-10-09
CN1972921B (zh)	2012-01-04
CN1972921A (zh)	2007-05-30
IL178757A0 (en)	2007-02-11
WO2005103028A1 (en)	2005-11-03
CA2564442A1 (en)	2005-11-03
BRPI0418765B8 (pt)	2021-05-25
KR100749566B1 (ko)	2007-08-16

Legal Events

Date	Code	Title	Description
2015-09-28	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20064771L (no)	2007-01-19	2-pyridyl substituerte imidazoler som ALK5 og/eller ALK4 inhibitorer
UA106136C2 (uk)	2014-07-25	2-піридилзаміщені імідазоли як терапевтичні інгібітори alk5 і/або alk4
ATE457311T1 (de)	2010-02-15	Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
NO20064015L (no)	2006-11-23	Kondenserte derivater av pyrazol
NO20092470L (no)	2009-08-27	Substituerte diazepanforbindelser som orexinreseptorantagonister
DK2175859T3 (da)	2012-06-18	Kondenserede heteroarylpyridyl- og phenylbenzen-sulfonamider som ccr2-modulatorer til behandling af inflammation
NO20073628L (no)	2007-07-16	Pyridoner som er nyttige som inhibitorer av kinaser
MX2009009592A (es)	2009-11-10	Aminopiridinas utiles como inhibidores de proteinas cinasas.
NO20083501L (no)	2008-10-14	Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
NO20093009L (no)	2009-12-17	Kondensert ring heterocykel kinase modulatorer
NO20051985L (no)	2005-06-09	Indazoler, benzotiazoler og benzoisotiazoler, samt fremstilling og anvendelser derav.
NO20072352L (no)	2007-05-31	Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
NO20084747L (no)	2008-11-25	Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
MX2009009591A (es)	2009-11-10	Aminopirimidinas utiles como inhibidores de proteinas cinasas.
NO20070487L (no)	2007-03-05	3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
EA201170659A1 (ru)	2011-10-31	Антитела к рецептору ii tgf-вета
MX2009006345A (es)	2009-06-23	Compuestos utiles como inhibidores de proteina cinasa.
NO20083406L (no)	2008-10-13	FGF-reseptorer for dimere forbindelser
NO20082684L (no)	2008-08-15	F-, G-, H-, I- og K-krystallformer av imatinibmesylat
IL188942A0 (en)	2008-04-13	Benzimidazole derivatives and pharmaceutical compositions containing the same
NO20092130L (no)	2009-06-17	Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase
NO20065622L (no)	2007-02-02	H-indazoler, benzotiazoler, 1,2-benzoisoksazoler, 1,2-benzoisotiazoler og kromoner, og fremstilling og anvendelser derav.
JO2645B1 (en)	2012-06-17	Vehicles
NO20074414L (no)	2007-11-05	1-H-pyrrol-2-karboksamider og imidazol-5-karboksamider og anvendelse derav for FAK, KDR og TIE2 kinasemodulatorer for behandling av kreft
ATE542795T1 (de)	2012-02-15	Benzylpiperazinderivate als motilin- rezeptorantagonisten